GEHC
GE HealthCare Technologies Inc.
GEHC's fundamentals are mixed: free cash flow grew 35%, but earnings per share fell 2.5%. At 17x earnings, it's trading in line with its usual 19x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GEHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
GEHC's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GEHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $71.95 | -12% |
| Forward | 15x | $81.84 | — |
| Current | 17x | $81.84 | — |
| Fair | 19x | $87.98 | +7.5% |
| Expensive | 24x | $111 | +36% |
Historical ranges are pointers, not guarantees.
GEHC's PE is in its fair range at 17x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GEHC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
GEHC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GEHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.35 | +13% |
| Q3 2026 | $4.73 | -2.5% |
| Q2 2026 | $4.35 | -11% |
| Q1 2026 | $4.17 | -12% |
| Q4 2025 | $4.55 | +4.8% |
| Q3 2025 | $4.85 | +33% |
| Q2 2025 | $4.89 | +42% |
| Q1 2025 | $4.76 | +39% |
| Q4 2024 | $4.34 | +43% |
GEHC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GEHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.5B | +7.2% |
| Q2 2026 | $5.3B | +5.8% |
| Q1 2026 | $5.1B | +7.4% |
| Q4 2025 | $5.7B | +7.1% |
| Q3 2025 | $5.1B | +5.8% |
| Q2 2025 | $5B | +3.5% |
| Q1 2025 | $4.8B | +2.7% |
| Q4 2024 | $5.3B | +2.2% |
GEHC's revenue has grown year over year for 10 quarters in a row: $5.5B last quarter, up 7.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.9 points |
| Q2 2026 | 14% | +0.9 points |
| Q1 2026 | 10% | -3.1 points |
| Q4 2025 | 15% | -0.6 points |
| Q3 2025 | 13% | -1.2 points |
| Q2 2025 | 13% | +0.5 points |
| Q1 2025 | 13% | +1.6 points |
| Q4 2024 | 15% | +1.8 points |
GEHC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GEHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GEHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $793M | +64% |
| Q2 2026 | $68M | +750% |
| Q1 2026 | $112M | +14% |
| Q4 2025 | $916M | +13% |
| Q3 2025 | $483M | -26% |
| Q2 2025 | $8M | +$191M |
| Q1 2025 | $98M | -64% |
| Q4 2024 | $811M | -15% |
GEHC generated $1.9B in free cash flow over the past year, up 35% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GEHC on cash flow, with more consistent year-over-year improvement.
GEHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -1M shares |
| 1 year | -0.9% | -4M shares |
| 3 years | -1.1% | -5M shares |
| 5 years | -0.4% | -1.7M shares |
GEHC has 453M diluted shares, down 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $200M |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $100M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
GEHC spent $300M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GEHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GEHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.4x | Moderate |
GEHC's net debt is about 2.0 years of its operating earnings (EBITDA), down from 2.5 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GEHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 82.0 | Overbought |
GEHC's weekly RSI is 65 (neutral) and its Stochastic is 82 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GEHC PE vs Healthcare Sector
| Metric | GEHC | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 33% below |
| PE % | 42 | 42 | Same percentile |
GEHC is trading at 17x earnings, a 33% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GEHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 13% above |
| 20 week MA | $69.5 | 18% above |
| 50 week MA | $72.1 | 13% above |
| 100 week MA | $74.2 | 10% above |
| 200 week MA | $76.6 | 6.9% above |
GEHC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GEHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $58.4 | $77.3 | +32% |
| 2024 | $77.3 | $79.5 | +2.8% |
| 2025 | $79.5 | $83.6 | +5.2% |
| 2026 YTD | $83.6 | $81.8 | -2.1% |
GEHC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.